Patent intelligence Β· US
US 2017136004
Opioid Agonist Antagonist Combinations
Opioid Agonist Antagonist Combinations
Patent details β US 2017136004
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 18, 2017
- Expiration
- May 13, 2037
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- CPC classes
- A61K 31/ 485 A I, A61K 31/ 4748 A I, A61K 45/ 06 A I, A61K/31135
Quick answer
US 2017136004 (Opioid Agonist Antagonist Combinations) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted May 18, 2017. Expires May 13, 2037 (11 years remaining) β relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- Grant date
- Expiration
- Claims
- β
- CPC classes
- A61K 31/ 485 A I, A61K 31/ 4748 A I, A61K 45/ 06 A I, A61K/31135, A61K/31137, A61K/31138
More from ALKERMES PHARMA IRELAND LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022263543
Pharmaceutical compositions comprising sorbitan esters
granted -
US 2023302008
METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE
granted -
WO 2023156493
FORMES CRISTALLINES DE NALTREXONE
granted -
WO 2023154894
COMPOSITIONS ET PROCΓDΓS D'IMMUNOTHΓRAPIE ANTICANCΓREUSE
granted -
CY 2022006
Ξ Ξ‘ΞΞ¦ΞΞ‘ΞΞΞΞ Ξ¦ΞΞ₯ΞΞΞ‘ΞΞΩΠΞΞΞ΀ΩΠΞΞΠΠΧΑΞΣΠ΀ΞΞ₯Ξ£ Σ΀ΞΞ ΞΞΞ©ΞΞ Ξ ΞΞΞΞΞΩΠΞΞΣΩΞ
granted -
US 2022354866
IMMEDIATE RELEASE MULTILAYER TABLET
granted -
CA 3172871
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted -
CA 3172874
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted
Frequently asked questions
What is US patent 2017136004?
US 2017136004 (Opioid Agonist Antagonist Combinations) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted May 18, 2017. Expires May 13, 2037 (11 years remaining) β relevant for patent-cliff and LOE planning.
Who owns US 2017136004?
ALKERMES PHARMA IRELAND LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2017136004 expire?
Our index shows an expiration date of May 13, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.